Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation

Cancer

Volumn 117, Issue 20, 2011, Pages 4671-4678

  Choe, Kevin S ^a   Haraf, Daniel J ^b   Solanki, Abhishek ^b   Cohen, Ezra E W ^b   Seiwert, Tanguy Y ^b   Stenson, Kerstin M ^b   Blair, Elizabeth A ^b   Portugal, Louis ^b   Villaflor, Victoria M ^b   Witt, Mary Ellyn ^b   Vokes, Everett E ^b   Salama, Joseph K ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

chemoradiotherapy; head and neck cancer; prognostic factor; recurrent and second primary; reirradiation

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IRIDIUM 192; IRINOTECAN; PACLITAXEL; PEMETREXED;

ADULT; AGED; ARTICLE; BONE NECROSIS; BRACHIAL PLEXUS NEUROPATHY; BRACHYTHERAPY; BRAIN NECROSIS; CANCER RECURRENCE; CANCER SURVIVAL; CAROTID ARTERY DISEASE; CAROTID HEMORRHAGE; CHEMORADIOTHERAPY; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG FATALITY; DYSPHAGIA; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; MUTISM; MYELITIS; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; SPEECH DISORDER; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DOSE FRACTIONATION; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; HYDROXYUREA; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RADIOTHERAPY DOSAGE; RETREATMENT; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; TREATMENT OUTCOME;

EID: 80053929394     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26084     Document Type: Article

References (50)

1. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350: 1945-1952. (Pubitemid 38580197)
2. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350: 1937-1944.
3. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349: 2091-2098. (Pubitemid 37464533)
4. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357: 1705-1715. (Pubitemid 350005152)
5. Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys. 1989; 17: 449-456. (Pubitemid 19227546)
6. Lin K, Patel SG, Chu PY, et al. Second primary malignancy of the aerodigestive tract in patients treated for cancer of the oral cavity and larynx. Head Neck. 2005; 27: 1042-1048. (Pubitemid 41705581)
7. Spector JG, Sessions DG, Haughey BH, et al. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope. 2001; 111: 1079-1087. (Pubitemid 32523720)
8. Vikram B, Strong EW, Shah JP, Spiro R,. Second malignant neoplasms in patients successfully treated with multimodality treatment for advanced head and neck cancer. Head Neck Surg. 1984; 6: 734-737. (Pubitemid 14185491)
9. Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR,. Salvage surgery following radiation failure in squamous cell carcinoma of the supraglottic larynx. Int J Radiat Oncol Biol Phys. 1995; 32: 605-609.
10. Taussky D, Dulguerov P, Allal AS,. Salvage surgery after radical accelerated radiotherapy with concomitant boost technique for head and neck carcinomas. Head Neck. 2005; 27: 182-186. (Pubitemid 40315766)
11. Forastiere AA, Leong T, Rowinsky E, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol. 2001; 19: 1088-1095. (Pubitemid 32176285)
12. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992; 10: 1245-1251.
13. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005; 23: 3562-3567.
14. Langendijk JA, Kasperts N, Leemans CR, Doornaert P, Slotman BJ,. A phase II study of primary reirradiation in squamous cell carcinoma of head and neck. Radiother Oncol. 2006; 78: 306-312.
15. Law SC, Lam WK, Ng MF, Au SK, Mak WT, Lau WH,. Reirradiation of nasopharyngeal carcinoma with intracavitary mold brachytherapy: an effective means of local salvage. Int J Radiat Oncol Biol Phys. 2002; 54: 1095-1113. (Pubitemid 35292622)
16. Stevens KR Jr, Britsch A, Moss WT,. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys. 1994; 29: 687-698. (Pubitemid 24241307)
17. Weichselbaum RR, Dahlberg W, Beckett M, et al. Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head-and neck-cancer patients. Proc Natl Acad Sci U S A. 1986; 83: 2684-2688. (Pubitemid 16026948)
18. De Crevoisier R, Bourhis J, Domenge C, et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol. 1998; 16: 3556-3562. (Pubitemid 28506768)
19. Hong WK, Bromer R,. Chemotherapy in head and neck cancer. N Engl J Med. 1983; 308: 75-79. (Pubitemid 13221186)
20. Haraf DJ, Weichselbaum RR, Vokes EE,. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol. 1996; 7: 913-918. (Pubitemid 26426265)
21. Milano MT, Vokes EE, Salama JK, et al. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005; 61: 1096-1106. (Pubitemid 40340903)
22. Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006; 64: 382-391. (Pubitemid 43083422)
23. Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol. 2008; 26: 5518-5523.
24. Spencer SA, Harris J, Wheeler RH, et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2001; 51: 1299-1304. (Pubitemid 33116324)
25. Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008; 30: 281-288. (Pubitemid 351480742)
26. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and 2 schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003; 21: 92-98.
27. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998; 338: 1798-1804. (Pubitemid 28277960)
28. Brockstein B, Haraf DJ, Stenson K, et al. A phase I-II study of concomitant chemoradiotherapy with paclitaxel (1-hour infusion), 5-fluorouracil and hydroxyurea with granulocyte colony stimulating factor support for patients with poor prognosis head and neck cancer. Ann Oncol. 2000; 11: 721-728.
29. Haraf DJ, Vokes EE, Panje WR, Weichselbaum RR,. Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol. 1991; 14: 419-426.
30. Haraf DJ, Vokes EE, Weichselbaum RR, Panje WR,. Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope. 1992; 102: 630-636.
31. Salama JK, Haraf DJ, Stenson K, Milano MT, Witt ME, Vokes EE,. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. Cancer J. 2005; 11: 140-146. (Pubitemid 44698825)
32. Seiwert TY, Haraf DJ, Cohen EE, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008; 26: 1732-1741.
33. Villaflor VM, Cohen EE, Haraf DJ, et al. Phase II trial pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated head and neck patients. Annals Oncol. 2011 Mar 8 [Epub ahead of print].
34. Vokes EE, Haraf DJ, Mick R, McEvilly JM, Weichselbaum RR,. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol. 1994; 12: 2351-2359. (Pubitemid 24346707)
35. Vokes EE, Panje WR, Schilsky RL, et al. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol. 1989; 7: 761-768. (Pubitemid 19145598)
36. Langer CJ, Harris J, Horwitz EM, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol. 2007; 25: 4800-4805. (Pubitemid 350086484)
37. De Crevoisier R, Domenge C, Wibault P, et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer. 2001; 91: 2071-2076. (Pubitemid 32476371)
38. Kowalski LP,. Results of salvage treatment of the neck in patients with oral cancer. Arch Otolaryngol Head Neck Surg. 2002; 128: 58-62. (Pubitemid 34052086)
39. Lee N, Chan K, Bekelman JE, et al. Salvage re-irradiation for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007; 68: 731-740. (Pubitemid 46818729)
40. Levendag PC, Meeuwis CA, Visser AG,. Reirradiation of recurrent head and neck cancers: external and/or interstitial radiation therapy. Radiother Oncol. 1992; 23: 6-15.
41. Mendenhall WM, Mendenhall CM, Malyapa RS, Palta JR, Mendenhall NP,. Re-irradiation of head and neck carcinoma. Am J Clin Oncol. 2008; 31: 393-398.
42. Pomp J, Levendag PC, van Putten WL,. Reirradiation of recurrent tumors in the head and neck. Am J Clin Oncol. 1988; 11: 543-549.
43. Tanvetyanon T, Padhya T, McCaffrey J, et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol. 2009; 27: 1983-1991.
44. Seiwert TY, Salama JK, Vokes EE,. The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol. 2007; 4: 86-100.
45. Balermpas P, Hambek M, Seitz O, Rodel C, Weiss C,. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. Strahlenther Onkol. 2009; 185: 775-781.
46. Cohen EE, Rosine D, Haraf DJ, et al. Phase I trial of tirapazamine, cisplatin, and concurrent accelerated boost reirradiation in patients with recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 678-684. (Pubitemid 46215895)
47. Vokes EE, Seiwert TY, Blair EE, et al. A phase I dose escalation study of Ad Gv.EGR.TNF. 11D (TNFerade) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer (HNC) [abstract]. J Clin Oncol. 2008; 26 (15S). Abstract 6067.
48. Licitra LF, Perrone F, Tamborini E, et al. Effect of antityrosyne kinase agents on in vitro tumor cell proliferation induced by wound drainage fluids (WDFs) of head and neck cancer (HNSCC) patients [abstract]. J Clin Oncol. 2008; 26 (15S). Abstract 6077.
49. Roh KW, Jang JS, Kim MS, et al. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2009; 74: 1348-1355.
50. Sulman EP, Schwartz DL, Le TT, et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys. 2009; 73: 399-409.